MILAN, ITALY--(Marketwire - December 13, 2007) - Recordati announced the successful conclusion of its acquisition of Orphan Europe, a European pharmaceutical group specialized in rare diseases, announced on 28 September last, following clearance from the relevant competition authorities. The price paid is of EUR 135 million.
